multi omics data (Foundation Medicine Inc)
Foundation Medicine Inc is a verified supplier 
Foundation Medicine Inc manufactures this product 
99
Structured Review
Foundation Medicine Inc
multi omics data
Multi Omics Data, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2282 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multi+omics+data/FoundationOne+CDx/pm42034603-270-30-37
Average 99 stars, based on 2282 article reviews
Multi Omics Data, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2282 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multi+omics+data/FoundationOne+CDx/pm42034603-270-30-37
Average 99 stars, based on 2282 article reviews
multi omics data - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
Analysis:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Next-Generation Sequencing:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Sequencing:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Tissue:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Oligomer Restriction:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Positron Emission Tomography:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Positron Emission Tomography-Computed Tomography:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Formalin-fixed Paraffin-Embedded:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Expressing:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the Selection:Article Title: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study Article Snippet: (80% CI 35–60) in 32 patients with EGFR-mutated advanced NSCLC and MET alterations following first-line osimertinib (based on NGS analysis of a tumor biopsy, using standard reported variants from the |